In general, HDAC inhibitors have been found to upregulate NK activation receptor NKG2D on NK cells as well its ligand MHC class I–related genes (MIC) on tumor cells resulting in enhanced NK-cell mediated recognition and killing in hematological and solid tumors (160–162). This evidence concerns the gene HDAC9 and neoplasm.